Abbott Laboratories

NYSE:ABT Rapport sur les actions

Capitalisation boursière : US$178.4b

Abbott Laboratories Croissance future

Future contrôle des critères 2/6

Abbott Laboratories devrait augmenter ses bénéfices et son chiffre d'affaires de 16.6% et de 7.6% par an respectivement. Le BPA devrait croître de de 16.9% par an. Le rendement des capitaux propres devrait être 20.3% dans 3 ans.

Informations clés

16.6%

Taux de croissance des bénéfices

16.91%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices17.0%
Taux de croissance des recettes7.6%
Rendement futur des capitaux propres20.32%
Couverture par les analystes

Good

Dernière mise à jour14 Sep 2026

Mises à jour récentes de la croissance future

Recent updates

Seeking Alpha • Aug 19

Abbott Laboratories: Reasonably Valued After Surge, But Still An Attractive Buy Long-Term

Summary Abbott Laboratories remains a buy, with accelerating earnings growth, margin expansion, and robust segment performance following Q2’s double beat and guidance raise. ABT’s Exact Sciences acquisition strengthens its long-term growth runway, supporting a raised EPS outlook and 10.4% CAGR over the next six years. Despite recent price appreciation, ABT trades below its 5-year forward P/E average, offering a 2.5% yield and a potential 37% upside to a $151 price target. Risks include Nutrition segment volatility, regulatory scrutiny on the pipeline, and international exposure, but ABT’s A credit rating and Dividend King status support a premium valuation. Read the full article on Seeking Alpha
Mise à jour du récit • Jul 23

ABT: Cancer Diagnostics Expansion And Dividend Streak Will Drive Future Repricing

Abbott Laboratories' fair value estimate has moved from $116.54 to $119.13. This reflects analysts' higher price targets in the $112 to $121 range after Q2 results that were viewed as better than expected and supported by updated models and confidence in longer term growth drivers.
Article d’analyse • Jun 21

Abbott Laboratories (ABT) Stock Could Be 24% Below Fair Value Before Earnings

Dividend affirmation and earnings catalyst put Abbott Laboratories stock in focus Recent commentary on Abbott Laboratories (ABT) has centered on upcoming earnings and Citi highlighting the value of its diversified healthcare businesses, setting the stage for closer attention to the stock. The reaffirmed quarterly dividend and the approaching July 16 earnings report give investors timely reference points as they weigh Abbott Laboratories stock, its current business mix, and expectations around...
Mise à jour du récit • Jun 16

ABT: Cancer Diagnostics Expansion And Dividend Streak Will Support Future Repricing

Analysts have nudged their fair value estimate for Abbott Laboratories slightly lower from about $117.29 to $116.54, reflecting a series of reduced Street price targets that cite utilization and inflation headwinds, while still applying a modestly lower discount rate and a slightly softer future P/E assumption. Analyst Commentary Recent Street research on Abbott Laboratories points to a more cautious tone, with many price targets cut and utilization and inflation flagged as key issues.
Mise à jour du récit • Jun 02

ABT: Cancer Diagnostics Expansion And Dividend Streak Will Support Future Repricing

Analysts have nudged their fair value estimate for Abbott Laboratories slightly lower to about $117.29 from $118.64. This reflects a series of reduced price targets and more cautious outlooks on growth and valuation across recent research updates.
Mise à jour du récit • May 12

ABT: Medtech Pipeline And Dividend Record Will Support Future Repricing

Analysts have trimmed Abbott Laboratories' consolidated price target by $1, reflecting a slightly higher discount rate, a marginally lower revenue growth outlook, a very small adjustment to profit margin assumptions, and a modestly lower future P/E multiple in light of several recent target cuts and a removal from a conviction list. Analyst Commentary Recent Street research on Abbott Laboratories has tilted more cautious, with a series of price target reductions and a removal from a major conviction list.
Mise à jour du récit • Apr 23

ABT: AF Portfolio And Dividend Track Record Will Support Future Repricing

Analysts have trimmed Abbott Laboratories' implied fair value estimate to $118.64 from $131.44. This reflects a series of recent price target reductions as they factor in updated growth, margin and P/E assumptions.
Mise à jour du récit • Apr 09

ABT: AF Portfolio And Dividend Track Record Will Support Future Upside

Abbott Laboratories' updated analyst price target reflects a modest reset, with fair value moving from $132.64 to $131.44 as analysts factor in higher assumed revenue growth of 10.24%, a lower profit margin of 15.60% and a slightly richer future P/E of 30.91x. Analyst Commentary Recent research on Abbott Laboratories points to an active debate around how much investors should pay for the stock, with several price target changes clustered over the past few months.
Mise à jour du récit • Mar 26

ABT: AF Portfolio Advancements And Dividend Streak Will Support Future Upside

Analysts have trimmed Abbott Laboratories' fair value estimate by about $0.70 to $132.64. This reflects a series of recent target cuts across the Street, even as they continue to reference generally healthy medtech sector fundamentals.
Mise à jour du récit • Mar 11

ABT: AF Portfolio Progress And Dividend Streak Will Drive Future Upside

Analysts have trimmed their average price targets on Abbott Laboratories by a few dollars, reflecting slightly higher required returns and refreshed assumptions on fair value, while still grounding their views in recent research that includes both target cuts and at least one upward revision. Analyst Commentary Recent research on Abbott Laboratories gives you a mixed but useful read on how the Street is thinking about valuation, execution, and growth.
Mise à jour du récit • Feb 24

ABT: Exact Sciences Deal And AF Portfolio Will Reshape Future Upside

Analyst targets on Abbott Laboratories have moved lower by double digit dollar amounts, with multiple firms trimming their price objectives in U.S. dollars as they factor in updated assumptions on discount rates, long term revenue growth, margins and future P/E expectations. Analyst Commentary Recent Street research on Abbott Laboratories reflects a mix of caution on valuation and optimism around the company’s longer term positioning, with several firms resetting price targets and one firm upgrading the stock.
Mise à jour du récit • Feb 10

ABT: Exact Sciences Deal Will Reshape Testing Franchise And Future Upside

Analysts have trimmed their fair value estimate for Abbott Laboratories by about $3 to roughly $133. This reflects modestly softer revenue growth assumptions, a slightly lower future P/E multiple near 30x, and recent reductions in price targets across several firms, even as some still highlight the pending Exact Sciences deal as a key part of their thesis.
Mise à jour du récit • Jan 26

ABT: Exact Sciences Acquisition Will Shape Future Earnings Mix And Upside Potential

Analysts have reduced their fair value estimate for Abbott Laboratories by about $8 to $136.47, reflecting a series of recent price target cuts that incorporate slightly adjusted growth, discount rate and P/E assumptions, along with expectations for a modestly higher profit margin profile. Analyst Commentary Recent research updates show a mix of optimism and caution around Abbott Laboratories, with several firms adjusting price targets and factoring in the pending Exact Sciences acquisition.
Mise à jour du récit • Jan 11

ABT: Exact Sciences Deal And Legal Wins Will Support Future Upside

Narrative Update Overview The updated analyst work on Abbott Laboratories reflects a small increase in the implied fair value to about $144.75. Analysts point to a tighter discount rate, steady growth and margin assumptions, and a blended view of recent price target changes that factor in medical devices momentum, the pending Exact Sciences deal, and reduced legal overhangs.
Article d’analyse • Jan 03

Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT)

What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...
Mise à jour du récit • Dec 27

ABT: Exact Sciences Deal And Legal Wins Will Drive Future Returns

Analysts modestly raised their average price target for Abbott Laboratories to about $144 per share, citing resilient mid-single digit organic revenue growth, double digit earnings power supported by a diversified healthcare portfolio, accelerating momentum in Medical Devices despite some near term lumpiness, and potential strategic upside from the pending Exact Sciences acquisition at a premium takeout valuation. Analyst Commentary Street research remains broadly constructive on Abbott, with recent notes highlighting both upside drivers and areas of near term scrutiny as investors digest the Exact Sciences transaction and mixed quarterly optics.
Mise à jour du récit • Dec 12

ABT: Exact Sciences Deal And Legal Wins Will Drive Future Upside

Analysts made a modest adjustment to their Abbott Laboratories price targets, with estimates moving in a roughly $2 range around the mid-$140s as they balanced optimism around the pending Exact Sciences acquisition, resilient device driven growth, and favorable legal developments against some near term lumpiness in non device segments. Analyst Commentary Research coverage around Abbott remains largely constructive, with most views anchored on a durable devices growth profile, incremental benefits from the proposed Exact Sciences transaction, and diminishing legal overhangs.
Mise à jour du récit • Nov 28

ABT: Exact Sciences Acquisition And Legal Wins Will Drive Medium-Term Upside

Abbott Laboratories’ analyst price target saw a modest decrease to $144.43 as analysts point to shifting expectations around profit margin and a slightly higher discount rate. This development is tempered by optimism for ongoing revenue growth and stability in core medical device performance.
Mise à jour du récit • Nov 14

ABT: Momentum From Legal Win And Product Approvals Will Support Future Gains

Analysts have modestly revised their price targets for Abbott Laboratories, with recent updates ranging from $142 to $146 per share. They cite strong momentum in Medical Devices and a resilient, diversified business model, despite varied performance across business segments.
Article d’analyse • Nov 05

Abbott Laboratories' (NYSE:ABT) Earnings Are Weaker Than They Seem

Abbott Laboratories ( NYSE:ABT ) announced strong profits, but the stock was stagnant. Our analysis suggests that...
Mise à jour du récit • Oct 31

ABT: Legal Wins And Device Momentum Will Support Durable Growth Ahead

Abbott Laboratories' average analyst price target experienced a modest increase to approximately $144.47. Analysts cited positive legal developments and continued momentum in the Medical Devices segment as key factors supporting the adjustment.
Mise à jour du récit • Oct 16

Expanding Emerging Markets And Diagnostics Will Drive Prospects Despite Headwinds

Analysts have modestly increased their price target for Abbott Laboratories from $142.48 to $144.40, citing resilient growth in medical devices and expectations for steady double-digit earnings growth, even though there may be some near-term variability across business segments. Analyst Commentary Recent research notes reflect a mix of optimism and caution from analysts following Abbott Laboratories' latest results and updates to price targets.

Prévisions de croissance des bénéfices et des revenus

NYSE:ABT - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202858,2478,9069,59211,90021
12/31/202754,5287,9788,92111,04127
12/31/202650,2046,3037,5479,40527
6/30/202646,5855,4017,8249,905N/A
3/31/202645,1346,2527,3789,464N/A
12/31/202544,3286,5007,3959,566N/A
9/30/202543,84313,9756,9179,119N/A
6/30/202543,10913,9776,7759,037N/A
3/31/202542,34413,5006,6578,950N/A
12/31/202441,95013,4006,3518,558N/A
9/30/202441,2175,7616,4868,728N/A
6/30/202440,7255,5465,6547,900N/A
3/31/202440,3265,6084,9237,143N/A
12/31/202340,1095,7005,0597,261N/A
9/30/202339,9595,1424,4926,549N/A
6/30/202340,2265,1405,4887,452N/A
3/31/202341,5055,7856,8238,659N/A
12/31/202243,6536,9057,8049,581N/A
9/30/202245,0307,8578,54110,322N/A
6/30/202245,5488,5208,46810,243N/A
3/31/202244,5147,6958,1529,961N/A
12/31/202143,0757,0428,64810,533N/A
9/30/202142,3087,2089,31411,264N/A
6/30/202140,2336,3438,64410,629N/A
3/31/202137,3385,6937,6099,823N/A
12/31/202034,6084,4495,7247,901N/A
9/30/202032,2213,3464,5876,519N/A
6/30/202031,4443,0734,5646,401N/A
3/31/202032,0953,539N/A6,139N/A
12/31/201931,9043,666N/A6,136N/A
9/30/201931,3553,272N/A5,485N/A
6/30/201930,9352,867N/A5,720N/A
3/31/201930,7232,582N/A5,904N/A
12/31/201830,5782,319N/A6,300N/A
9/30/201830,402802N/A6,175N/A
6/30/201829,575812N/A5,997N/A
3/31/201828,445365N/A6,104N/A
12/31/201727,390344N/A5,570N/A
9/30/201725,1341,971N/A5,100N/A
6/30/201723,6071,055N/A4,312N/A
3/31/201722,3031,384N/A3,870N/A
12/31/201620,8531,056N/A3,203N/A
9/30/201620,708989N/A2,861N/A
6/30/201620,5561,939N/A2,839N/A
3/31/201620,3932,124N/A2,871N/A
12/31/201520,4052,586N/A2,966N/A
9/30/201520,5732,523N/A3,376N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de ABT ( 16.6% par an) est supérieure au taux d'épargne ( 3.7% ).

Bénéfices vs marché: Les bénéfices de ABT ( 16.6% par an) devraient croître plus lentement que le marché US ( 17.1% par an).

Croissance élevée des bénéfices: Les bénéfices de ABT devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ABT ( 7.6% par an) devrait croître plus lentement que le marché de US ( 13.3% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ABT ( 7.6% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de ABT devrait être élevé dans 3 ans ( 20.3 %)

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/09/15 04:06
Cours de l'action en fin de journée2026/09/15 00:00
Les revenus2026/06/30
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Abbott Laboratories est couverte par 47 analystes. 27 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
David ToungArgus Research Company
David RescottBaird
Matthew MiksicBarclays